Last reviewed · How we verify
Apidra
At a glance
| Generic name | Apidra |
|---|---|
| Also known as | Glulisine, Insulin glulisine, Glulisine insulin |
| Sponsor | Kinderkrankenhaus auf der Bult |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus
Common side effects
- Hypoglycemia
- Allergic reactions
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
- Weight gain
- Catheter occlusions
- Infusion site reactions
Serious adverse events
- Severe symptomatic hypoglycemia
- Anaphylaxis
- Generalized allergy
- Dyspnea
- Wheezing
- Hypotension
- Tachycardia
- Diaphoresis
Key clinical trials
- The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (PHASE4)
- Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients (PHASE3)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- Degludec Glargine U300 Hospital Study (NA)
- Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) (PHASE4)
- Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) (NA)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apidra CI brief — competitive landscape report
- Apidra updates RSS · CI watch RSS
- Kinderkrankenhaus auf der Bult portfolio CI